A New Approach to Brain Health: The RECAP2 Study
Bottom line: The RECAP2 study is a Phase 1 trial exploring the effects of psilocybin, with or without midazolam, on brain function and emotional wellbeing in people with mild emotional decline, with results yet to be determined.
A Phase 1 trial is exploring how psilocybin might affect the brain when taken with midazolam or a placebo, focusing on its impact on neuroplasticity and emotional wellbeing in people with mild emotional decline.
The RECAP2 Study is testing four different medication combinations: psilocybin with midazolam, psilocybin with placebo, and two other control groups. Researchers are looking at how these combinations influence mood and brain function. Using MRI scans, TMS, and EEG, they’re tracking changes in brain activity and structure. Participants also complete questionnaires to assess their emotional state throughout the trial.
This research could help clarify how psilocybin might support brain plasticity — the brain’s ability to reorganize and form new connections — which is essential for learning, memory, and recovery from emotional distress. If the study finds that a specific combination improves mood or brain function, it could lead to more targeted approaches for mental health treatment.
What makes this trial particularly interesting is the inclusion of midazolam, a benzodiazepine typically used for sedation, alongside psilocybin. Early research suggests that combining these substances may influence how the brain processes emotional experiences during and after the session, potentially enhancing therapeutic outcomes.
This trial is still in the recruitment phase and has not yet produced results. Registration on ClinicalTrials.gov does not mean the intervention is safe, effective, or approved. Phase 1 studies are primarily about safety and how the body reacts to a treatment, not about whether it works. The findings from this trial should be seen as preliminary and not as proof of effectiveness.
To track the progress of the RECAP2 Study, visit the ClinicalTrials.gov record. This page will provide updates on recruitment, study design, and future milestones. Once results are available, they will be posted there as well.

Sources
https://clinicaltrials.gov/study/NCT06692192 | NCT06692192
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
Frequently asked questions
Is the RECAP2 Study safe for participants?
What is the purpose of the RECAP2 Study?
What are the different combinations being tested in the RECAP2 Study?
How are the effects of psilocybin being measured in the RECAP2 Study?
Where can I find updates on the RECAP2 Study?
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.